P1031: PRELIMINARY DATA FROM THE PHASE 1/2 STUDY OF TP-3654, AN INVESTIGATIONAL SELECTIVE PIM1 KINASE INHIBITOR, SHOWED CYTOKINE REDUCTION AND CLINICAL RESPONSES IN RELAPSED/REFRACTORY MYELOFIBROSIS

• Firas El Chaer,
• Lindsay Rein,
• Kazuya Shimoda,
• Junichiro Yuda,
• Tamanna Haque,
• James Mccloskey,
• Akiyoshi Takami,
• Masafumi Fukaya,
• Shuichi Shirane,
• Sujan Kabir,
• Jian Mei,
• Zhonggai LI,
• Mark Wade,
• Claudia Lebedinsky,
• Raajit K Rampal

Affiliations

Firas El Chaer

1 University of Virginia, Charlottesville, United States

Lindsay Rein

2 Duke University, Durham, United States

Kazuya Shimoda

3 University of Miyazaki, Miyazaki, Japan

Junichiro Yuda

4 National Cancer Center Hospital East, Chiba, Japan

Tamanna Haque

5 Memorial Sloan Kettering Cancer Center New York, New York, United States

James Mccloskey

6 John Theurer Cancer Center, Hackensack, United States

Akiyoshi Takami

7 Aichi Medical University School of Medicine, Aichi, Japan

Masafumi Fukaya

8 Shizuoka Cancer Center, Shizuoka, Japan

Shuichi Shirane

9 Juntendo University School of Medicine, Tokyo, Japan

Sujan Kabir

10 Sumitomo Pharma Oncology, Inc., Marlborough, United States

Jian Mei

10 Sumitomo Pharma Oncology, Inc., Marlborough, United States

Zhonggai LI

10 Sumitomo Pharma Oncology, Inc., Marlborough, United States

Mark Wade

10 Sumitomo Pharma Oncology, Inc., Marlborough, United States

Claudia Lebedinsky

10 Sumitomo Pharma Oncology, Inc., Marlborough, United States

Raajit K Rampal

5 Memorial Sloan Kettering Cancer Center New York, New York, United States